Table 12 (abstract P209). Patients’ characteristics at baseline
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two
|  | Etanercept-cohort N = 419 | Adalimumab -cohort N = 236 | Odd’s ratio# (95%CI); p | Tocilizumab-cohort N = 74 | Odd’s ratio# (95%CI); p |
|---|---|---|---|---|---|
Female, n (%) | 332 (79.2%) | 192 (81.4%) | 1.1 (0.7-1.5); 0.78 | 51 (68.8%) | 0.59 (0.38-0.94); 0.027 |
Age at baseline, mean+/- SD | 10.49+/-4.36 | 11.8 +/-4.0 | n.a.; <0.0001 | 13.90+/-3.63 | n.a.; <0.0001 |
JIA Category n(%) RF + PA/FR-PA/ExOA | 37 (8.8%)/224 (53.5%)/158 (37.7%) | 23 (9.7%)/128 (54.2%)/85 (36.0%) | n.s. | 9 (12.2%)/47 (63.5%)/18 (24.3%) | 0.58 (0.43-0.99); 0.03 |
First biologic used | 400 (95.5%) | 122 (51.7%) | 0.08 (0.05-0.14); <0.0001 | 15 (20.2%) | 0.02 (0.01-0.03); <0.0001 |
Co-Med MTX, n(%) | 309 (73.7) | 127 (53.8) | 0.51 (0.37-0.71); <0.0001 | 34 (45.9) | 0.43 (0.26-0.69); 0.0004 |
JADAS10 [0-40] mean +/-SD | 13.8 +/- 7.1 | 12.1 +/-7.6 | n.a.; 0.004 | 15.1 +/- 7.4 | n.s |
CHAQ-DI [0-3] mean +/-SD | 0.59 +/- 0.6 | 0.43 +/-0.58 | n.a.; <0.0001 | 0.63+/-0.55 | n.s. |
Uveitis before start of biologic | 23 (5.5%) | 59 (25%) | 5.73 (3.43-5.99); 0,0001 | 0 | n.a. |